|
Collaboration Arrangements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 26 Months Ended | 3 Months Ended | ||||
|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
|
Mar. 31, 2013
|
Mar. 31, 2014
Merck KGaA [Member]
|
Mar. 31, 2014
Merck KGaA [Member]
|
Mar. 31, 2014
Merck KGaA [Member]
United States [Member]
|
Mar. 31, 2014
Merck KGaA [Member]
Regulatory and Development Milestones [Member]
|
Mar. 31, 2014
Merck KGaA [Member]
Commercialization Milestones [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
| Upfront and milestone payments received to date | $ 12.5 | $ 110.0 | |||||
| Potential future milestones | 100 | 340 | |||||
| Merck KGaA's percentage share of worldwide development expenses | 70.00% | ||||||
| Portion of profits that Company is eligible to participate, depending upon total sales | 50.00% | ||||||
| Revenue recognized by the Company | 3.7 | 2.9 | |||||
| Company earned a reimbursement for eligible worldwide development expenses | $ 5.9 | $ 3.5 | |||||